In Brief: Pharmacia & Upjohn
Executive Summary
Pharmacia & Upjohn: NDA submitted July 16 for Rescriptor (delavirdine tablets) for treatment of AIDS. Delavirdine is a non-nucleoside reverse transcriptase inhibitor; FDA recently approved the first antiviral in that class, Boehringer Ingelheim's Viramune...